Skip to content
Medical Health Aged Care, Mental Health

IHACPA releases the Pricing Framework for Australian Public Hospital Services 2024-25

Independent Health and Aged Care Pricing Authority 2 mins read

The Independent Health and Aged Care Pricing Authority (IHACPA) has released the Pricing Framework for Australian Public Hospital Services 2024–25 (the Pricing Framework) following public consultation.

The Pricing Framework, updated annually, outlines the policy and evidence that will inform the development of the National Efficient Price (NEP) Determination 2024–25 (NEP24) and the National Efficient Cost (NEC) Determination 2024–25 (NEC24). 

The Australian Government will use these determinations to calculate their funding of Australian public hospital services in the 2024–25 financial year. 

Significant updates to the Pricing Framework include an intention to transition community mental health care from block funding to activity based funding and factoring ongoing financial pressures into the pricing model.

IHACPA Chair, Mr David Tune AO PSM said: ‘Developing a sustainable pricing model every year calls for a high level of collaboration and critical analysis to ensure funding of Australian public hospital services is transparent and equitable.’ 

For the first time, the Pricing Framework presents IHACPA’s intention to price community mental health care services using the Australian Mental Health Care Classification Version 1.0 for NEP24 after three years of shadow pricing. 

‘The transition from block funding to activity based funding in community mental health care is the culmination of over 10 years of work from IHACPA and stakeholders,’ Mr Tune said.

‘The important shift towards a consumer-centred classification and funding model will improve transparency and give more clarity to hospitals and service providers. It will also ensure funding is based on the volume, type and complexity of mental health care delivered in the community.’ 

The Pricing Framework also presents IHACPA’s approach to managing the ongoing impact of financial pressures on public hospital services following a year of collaboration with jurisdictions. It ensures changes in demand for hospital services, inflationary pressures and the higher costs associated with treating patients with COVID-19 are accounted for in the NEP and NEC Determinations for 2024–25. 

Other updates include: 

  • pricing the updated Australian National Subacute and Non-Acute Patient Classification Version 5.0 for NEP24 after two years of shadow pricing
  • introducing two new classes relating to the supervised administration of opioid agonist treatment and home-based subcutaneous immunoglobulin infusion treatment in non-admitted setting.

Each year, IHACPA updates the Pricing Framework to reflect healthcare changes. 

The latest version was developed following extensive consultation with jurisdictions and stakeholders, and analysis of 27 submissions received in response to IHACPA’s Consultation Paper on the Pricing Framework for Australian Public Hospital Services 2024–25

Submissions and a summary of feedback are available on IHACPA’s website.

IHACPA will release the final NEP and NEC Determinations in March 2024.


About us:

About IHACPA

IHACPA is an independent federal government agency that supports the Australian Government to fund public hospitals and aged care services more efficiently.

Established in 2011, IHACPA uses data and consults widely to determine the annual cost and price of public hospital services and provide advice to inform government decisions on the cost and price of aged care services.  


Contact details:

IHACPA Communications
0468 517 253 | [email protected]

More from this category

  • Medical Health Aged Care
  • 18/11/2025
  • 18:11
Debiopharm

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New “Ideal Japan” Program

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research…

  • Contains:
  • Medical Health Aged Care
  • 18/11/2025
  • 18:11
Amoeba

A natural breakthrough in protecting cereals and field crops

Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UKChassieu, France Basel, Switzerland , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Amoebas. These single-celled microorganisms are now at the heart of one of agriculture’s latest biological innovation – a bio-fungicide capable of protecting wheat and other cereal crops from crippling fungal diseases that cost global agriculture billions of dollars in annual crop losses and quality.This new development, made from the lysate of the amoeba Willaertia magna C2c Maky, holds strong potential to advance biological crop protection. In trials, the candidate demonstrated its effectiveness in combating the fungi…

  • Government TAS, Medical Health Aged Care
  • 18/11/2025
  • 14:28
TAS CAHRD and Hepatitis Australia

‘Ever had a tattoo back in the day?’ – New campaign urges Tasmanians to ‘get tested and get cured’ of hepatitis C

MEDIA RELEASE Embargoed until 11:59PM – Tuesday 18 November ‘Ever had a tattoo back in the day?’ New campaign urges Australians to ‘get tested and get cured’ for hepatitis C Media release: Wednesday, 19 November 2025 Ever had a tattoo back in the day? Or had a medical or cosmetic procedure, or body piercing overseas? Ever injected steroids or drugs? Even just once? You could have hepatitis C and not even know it… With men twice as likely to be affected by hepatitis C compared with women, that’s the key messageHepatitis Australia, in partnership withTasCAHRD, is putting front and centre…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.